Top Picks
Show
Signal
Opinion
Expert
TOP PICK
TOP PICK
September 30, 2020
Dominance of Humera on revenues had given them pause. Since then, it acquired Allergan, which diluted the concentration of Humera. Metrics are wonderful. 12% free cash flow yield. Trades at less than 10x earnings. Great dividend. Lots of runway ahead. Elective surgeries will come back. Anticipate $12.50 EPS this year, and more next. Yield is 5.42%. (Analysts’ price target is $109.35)
Show full opinionHide full opinion
Dominance of Humera on revenues had given them pause. Since then, it acquired Allergan, which diluted the concentration of Humera. Metrics are wonderful. 12% free cash flow yield. Trades at less than 10x earnings. Great dividend. Lots of runway ahead. Elective surgeries will come back. Anticipate $12.50 EPS this year, and more next. Yield is 5.42%. (Analysts’ price target is $109.35)
TOP PICK
TOP PICK
September 30, 2020
Structural materials for commercial aerospace. If you believe that aerospace will come back, and he does, this will be a good opportunity. No dividend. (Analysts’ price target is $40.53)
Show full opinionHide full opinionStructural materials for commercial aerospace. If you believe that aerospace will come back, and he does, this will be a good opportunity. No dividend. (Analysts’ price target is $40.53)
TOP PICK
TOP PICK
September 30, 2020
Came out of Kraft, as the snack piece. Growing well organically, 6.3% y/y. Prides itself on stability. Snacks are evolving; there are healthy options. Worldwide opportunity for expansion, sub-20x earnings, good dividend. The side of the barbell that gives stability to counteract the octane of tech. Yield is 2.21%. (Analysts’ price target is $62.96)
Show full opinionHide full opinionCame out of Kraft, as the snack piece. Growing well organically, 6.3% y/y. Prides itself on stability. Snacks are evolving; there are healthy options. Worldwide opportunity for expansion, sub-20x earnings, good dividend. The side of the barbell that gives stability to counteract the octane of tech. Yield is 2.21%. (Analysts’ price target is $62.96)
TOP PICK
TOP PICK
September 29, 2020
Stockchase Research Editor: Michael O'Reilly As the market valuations continue to be priced at perfection this is a defensive Top Pick. This low MER ETF tracks US 7-10 year Treasuries -- a safe haven during market down turns. What makes this interesting as well, from an Canadian investor's perspective, is that it is priced in Canadian dollars. This will add another kicker in a market down turn as we expect a flight to the US dollar safety at some point. We would buy this with a $60 stop-loss. Yield 0%
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly As the market valuations continue to be priced at perfection this is a defensive Top Pick. This low MER ETF tracks US 7-10 year Treasuries -- a safe haven during market down turns. What makes this interesting as well, from an Canadian investor's perspective, is that it is priced in Canadian dollars. This will add another kicker in a market down turn as we expect a flight to the US dollar safety at some point. We would buy this with a $60 stop-loss. Yield 0%
TOP PICK
TOP PICK
September 29, 2020
Stockchase Research Editor: Michael O'Reilly MRK is one of the largest pharma companies in the world. It trades at a 13 PE compared to 22 PE for the S&P500. The pandemic has slowed some elective procedures, and that has slowed sales in the latest quarter by about 9%. However, management still opted to raise its 2020 guidance showing confidence that things should improve for the balance of the year. The company also has three drugs moving through various COVID-19 vaccine test trials. It pays a good yield, backed by a 58% payout ratio. We would buy this with an upper target towards $96 as the first objective and use $77 as a stop-loss. Yield 2.95% (Analysts’ price target is $95.94)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly MRK is one of the largest pharma companies in the world. It trades at a 13 PE compared to 22 PE for the S&P500. The pandemic has slowed some elective procedures, and that has slowed sales in the latest quarter by about 9%. However, management still opted to raise its 2020 guidance showing confidence that things should improve for the balance of the year. The company also has three drugs moving through various COVID-19 vaccine test trials. It pays a good yield, backed by a 58% payout ratio. We would buy this with an upper target towards $96 as the first objective and use $77 as a stop-loss. Yield 2.95% (Analysts’ price target is $95.94)
TOP PICK
TOP PICK
September 29, 2020
Stockchase Research Editor: Michael O'Reilly In the search for a pandemic vaccine, JNJ is a potential winner. Leveraging off their proven technology with their Ebola, HIV and other vaccines, the company continues to develop a COVID-19 vaccine that presently shows strong immunity response in 99% of trials. It is also the only option that is testing a single-dose vaccine. Revenues have dipped 10% in the latest quarterly earnings, but that can be attributed to a slow down in elective procedures. It pays a good dividend backed by a 67% payout ratio. We would trade this with a stop-loss at $132. Yield 2.75% (Analysts’ price target is $165.06)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly In the search for a pandemic vaccine, JNJ is a potential winner. Leveraging off their proven technology with their Ebola, HIV and other vaccines, the company continues to develop a COVID-19 vaccine that presently shows strong immunity response in 99% of trials. It is also the only option that is testing a single-dose vaccine. Revenues have dipped 10% in the latest quarterly earnings, but that can be attributed to a slow down in elective procedures. It pays a good dividend backed by a 67% payout ratio. We would trade this with a stop-loss at $132. Yield 2.75% (Analysts’ price target is $165.06)
TOP PICK
TOP PICK
September 29, 2020
Focused on single-family rental homes in US and multi-family apartments in Toronto. The latter class has benefitted from the work-from-home trend as well as millennials looking for more space as they start families. Offers affordable middle-market homes at lower rents than high-rise apartment buildings. Still trades at a discount to NAV despite at a 98% occupancy. Loves management and its capital allocation plan. (Analysts’ price target is $2.28)
Show full opinionHide full opinionFocused on single-family rental homes in US and multi-family apartments in Toronto. The latter class has benefitted from the work-from-home trend as well as millennials looking for more space as they start families. Offers affordable middle-market homes at lower rents than high-rise apartment buildings. Still trades at a discount to NAV despite at a 98% occupancy. Loves management and its capital allocation plan. (Analysts’ price target is $2.28)
TOP PICK
TOP PICK
September 29, 2020
He's one of the biggest owners of this. They operate in the US sunbelt, like Dallas and Austin where the population is outpacing the country. A good operator. They offer growth and stability. Rents are affordable to target the middle market. Pays a good yield. Trades at a discount to NAV.
Show full opinionHide full opinionHe's one of the biggest owners of this. They operate in the US sunbelt, like Dallas and Austin where the population is outpacing the country. A good operator. They offer growth and stability. Rents are affordable to target the middle market. Pays a good yield. Trades at a discount to NAV.
TOP PICK
TOP PICK
September 29, 2020
Price target: 1.57 pounds Dublin becoming a tech hub and there's a housing shortage, so rents have been doubling there where North America has rent control. CAP REIT formed this years ago. Ireland has been a tax haven for foreign tech companies, so Ireland should benefit when these foreign workers return here.
Show full opinionHide full opinionPrice target: 1.57 pounds Dublin becoming a tech hub and there's a housing shortage, so rents have been doubling there where North America has rent control. CAP REIT formed this years ago. Ireland has been a tax haven for foreign tech companies, so Ireland should benefit when these foreign workers return here.
TOP PICK
TOP PICK
September 28, 2020
It is the dominant dollar store in the US. They feel they can add a thousand stores a year for the next decade or more. The ROI on these stores is two years. It is a growth story. (Analysts’ price target is $222.76)
Show full opinionHide full opinionIt is the dominant dollar store in the US. They feel they can add a thousand stores a year for the next decade or more. The ROI on these stores is two years. It is a growth story. (Analysts’ price target is $222.76)
TOP PICK
TOP PICK
September 28, 2020
The dominant health insurance company in the US. It is the first one to integrate the pharmacy, benefits and insurance payer all into one. They are generating a lot of good will during COVID. (Analysts’ price target is $344.96)
Show full opinionHide full opinionThe dominant health insurance company in the US. It is the first one to integrate the pharmacy, benefits and insurance payer all into one. They are generating a lot of good will during COVID. (Analysts’ price target is $344.96)
TOP PICK
TOP PICK
September 28, 2020
Own the designer of the chips rather than the cell phone. If you want to be in the tech space, this is the one. (Analysts’ price target is $398.55)
Show full opinionHide full opinionOwn the designer of the chips rather than the cell phone. If you want to be in the tech space, this is the one. (Analysts’ price target is $398.55)
TOP PICK
TOP PICK
September 25, 2020
Natural gas focus and infrastructure assets that are contracted on a long-term basis makes this a good opportunity. The dividend is well-covered on a sustained basis. Energy demands is poised to rise for a little while. It should return to pre-covid levels eventually. A quality company. (Analysts’ price target is $39.36)
Show full opinionHide full opinionNatural gas focus and infrastructure assets that are contracted on a long-term basis makes this a good opportunity. The dividend is well-covered on a sustained basis. Energy demands is poised to rise for a little while. It should return to pre-covid levels eventually. A quality company. (Analysts’ price target is $39.36)
TOP PICK
TOP PICK
September 25, 2020
The renewable energy transition is very positive. We have growing energy demand that needs to offset the growth even before replacing existing energy supplies. They have a big presence in the US. They just signed an agreement with Chevron to off-set carbon emissions. (Analysts’ price target is $20.50)
The renewable energy transition is very positive. We have growing energy demand that needs to offset the growth even before replacing existing energy supplies. They have a big presence in the US. They just signed an agreement with Chevron to off-set carbon emissions. (Analysts’ price target is $20.50)
TOP PICK
TOP PICK
September 25, 2020
You have to endure a little more volatility with the preferred shares. This preferred share does reset. It has a floor at the current dividend levels, which means it can only go up. If there is an inflation response, it will participate in that.
Show full opinionHide full opinionYou have to endure a little more volatility with the preferred shares. This preferred share does reset. It has a floor at the current dividend levels, which means it can only go up. If there is an inflation response, it will participate in that.
TOP PICK
TOP PICK
September 25, 2020
Billy Kawasaki’s Insights - Picks from 5i Research. A fund that is all equity so there is some market risk. It is large and liquid, offering a global exposure. 40% of assets are in the US, with 29% in Canada. There is no dividend withholding tax if in an RRSP. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Picks from 5i Research. A fund that is all equity so there is some market risk. It is large and liquid, offering a global exposure. 40% of assets are in the US, with 29% in Canada. There is no dividend withholding tax if in an RRSP. Unlock Premium - Try 5i Free
TOP PICK
TOP PICK
September 24, 2020
Stockchase Research Editor: Michael O'Reilly We are being rewarded for our patience and are making MMM a Top Pick following a recent pullback in the stock. As previously reported, the maker of the N95 masks has been in the spot light as they have directly been keeping front line workers safer during the pandemic. For 2020 they expect to have produced 2 billion of the masks and continue to partner with the US Department of Defense. The company is mulling over selling the food safety business for $3.5 billion -- 10 times annual revenues of the segment. The segment contributed 1% of total sales in 2019. Their health care segment is expected to pick up as well, after seeing a 12% yoy slowdown, as delays in elective procedures are removed. It has an attractive yield that is backed by a payout ratio of 65% of cash flow. We look for this to test $185 and would use $149 as a stop-loss. Yield 3.69% (Analysts’ price target is $166.47)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly We are being rewarded for our patience and are making MMM a Top Pick following a recent pullback in the stock. As previously reported, the maker of the N95 masks has been in the spot light as they have directly been keeping front line workers safer during the pandemic. For 2020 they expect to have produced 2 billion of the masks and continue to partner with the US Department of Defense. The company is mulling over selling the food safety business for $3.5 billion -- 10 times annual revenues of the segment. The segment contributed 1% of total sales in 2019. Their health care segment is expected to pick up as well, after seeing a 12% yoy slowdown, as delays in elective procedures are removed. It has an attractive yield that is backed by a payout ratio of 65% of cash flow. We look for this to test $185 and would use $149 as a stop-loss. Yield 3.69% (Analysts’ price target is $166.47)
TOP PICK
TOP PICK
September 24, 2020
Stochchase Research Editor: Michael O'Reilly PFE is a defensive Top Pick that pays a strong yield, with history of dividend growth and a strong balance sheet. It is one of the world's leading pharmaceutical companies with a robust pipeline of new products in development (targeting 25 new drugs to market by 2025). They are partnering to develop a COVID-19 vaccine that is now in stage 2/3 testing and has a contract with the US government for $1.95 billion for the first 100 million doses if successful. The company holds $1.8 billion in cash reserves. The yield is strong and is supported with a 58% payout ratio. We would buy this using a $31 stop-loss, looking for a return towards $42. Yield 4.22% (Analysts’ price target is $41.79)
Show full opinionHide full opinionStochchase Research Editor: Michael O'Reilly PFE is a defensive Top Pick that pays a strong yield, with history of dividend growth and a strong balance sheet. It is one of the world's leading pharmaceutical companies with a robust pipeline of new products in development (targeting 25 new drugs to market by 2025). They are partnering to develop a COVID-19 vaccine that is now in stage 2/3 testing and has a contract with the US government for $1.95 billion for the first 100 million doses if successful. The company holds $1.8 billion in cash reserves. The yield is strong and is supported with a 58% payout ratio. We would buy this using a $31 stop-loss, looking for a return towards $42. Yield 4.22% (Analysts’ price target is $41.79)
TOP PICK
TOP PICK
September 24, 2020
Stochchase Research Editor: Michael O'Reilly As the pandemic appears to be heading towards wave two, take-out vendors will continue to benefit. PZZA has done well thus far, with recently reported revenues rising by 15% over the year and sales up 28%. We recommend picking up this Top Pick with an eye to return return to $100 -- nearly a 20% return-- using $72 as stop-loss. Yield 1.05% (Analysts’ price target is $106.21)
Show full opinionHide full opinionStochchase Research Editor: Michael O'Reilly As the pandemic appears to be heading towards wave two, take-out vendors will continue to benefit. PZZA has done well thus far, with recently reported revenues rising by 15% over the year and sales up 28%. We recommend picking up this Top Pick with an eye to return return to $100 -- nearly a 20% return-- using $72 as stop-loss. Yield 1.05% (Analysts’ price target is $106.21)
TOP PICK
TOP PICK
September 24, 2020
Raised dividend for 57 years. Nice balance between drug business, consumer products, and diagnostics. Likely to see acquisitions in consumer and diagnostics. A beneficiary of the post-Covid environment. Long-term exposure to a global healthcare leader. Good valuation. Continued performance. Yield is 2.08%. (Analysts’ price target is $163.63)
Show full opinionHide full opinionRaised dividend for 57 years. Nice balance between drug business, consumer products, and diagnostics. Likely to see acquisitions in consumer and diagnostics. A beneficiary of the post-Covid environment. Long-term exposure to a global healthcare leader. Good valuation. Continued performance. Yield is 2.08%. (Analysts’ price target is $163.63)
TOP PICK
TOP PICK
September 24, 2020
Structural growth story for 3-5 years. Great exposure in US, with growing international presence. Really likes management. Healthy dividend that has grown at 9%. Yield is 2.09%. (Analysts’ price target is $39.11)
Show full opinionHide full opinionStructural growth story for 3-5 years. Great exposure in US, with growing international presence. Really likes management. Healthy dividend that has grown at 9%. Yield is 2.09%. (Analysts’ price target is $39.11)
TOP PICK
TOP PICK
September 24, 2020
Attractive entry point. Likes exposure to semis and consumer electronics. A world class business at a discounted price. Dividend has grown at 27% for the last 10 years. Asia is oversold, and so is best positioned for a post-Covid recovery. Yield is 2.41%. (Analysts’ price target is $1571.10)
Show full opinionHide full opinionAttractive entry point. Likes exposure to semis and consumer electronics. A world class business at a discounted price. Dividend has grown at 27% for the last 10 years. Asia is oversold, and so is best positioned for a post-Covid recovery. Yield is 2.41%. (Analysts’ price target is $1571.10)
TOP PICK
TOP PICK
September 23, 2020
Best in class. Rock solid balance sheet, outstanding leadership. Great investment banking, large digital presence. Well capitalized. Good valuation. Dividend sustainable. Election outcome won't have a negative impact. Yield is 3.82%. (Analysts’ price target is $114.86)
Show full opinionHide full opinionBest in class. Rock solid balance sheet, outstanding leadership. Great investment banking, large digital presence. Well capitalized. Good valuation. Dividend sustainable. Election outcome won't have a negative impact. Yield is 3.82%. (Analysts’ price target is $114.86)
TOP PICK
TOP PICK
September 23, 2020
Huge chunk of US retail deposits. Fantastic investment banking francise. CEO has done well navigating problems. Well capitalized. Trading at 0.8% of book value. Compelling opportunity. Exceptionally well run. Default rates not that bad. Growth is happening. Dividend sustainable. Election outcome won't have a negative impact. Yield is 3.01%. (Analysts’ price target is $27.77)
Show full opinionHide full opinionHuge chunk of US retail deposits. Fantastic investment banking francise. CEO has done well navigating problems. Well capitalized. Trading at 0.8% of book value. Compelling opportunity. Exceptionally well run. Default rates not that bad. Growth is happening. Dividend sustainable. Election outcome won't have a negative impact. Yield is 3.01%. (Analysts’ price target is $27.77)
TOP PICK
TOP PICK
September 23, 2020
Likes the deal with Reliance, the cell phone operator in India. Will drive further revenue growth. Moving full-on with e-commerce in India. Will provide attractive mediums for businesses to attract consumers. Great long-term hold. No dividend. (Analysts’ price target is $288.00)
Show full opinionHide full opinionLikes the deal with Reliance, the cell phone operator in India. Will drive further revenue growth. Moving full-on with e-commerce in India. Will provide attractive mediums for businesses to attract consumers. Great long-term hold. No dividend. (Analysts’ price target is $288.00)
TOP PICK
TOP PICK
September 23, 2020
Billy Kawasaki’s Insights - Picks from 5i Research. Management has proven themselves with a solid historical performance. They are long term holders and builders of businesses. Cash flow is good and they have turned a profit every year for the last 20 years. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Picks from 5i Research. Management has proven themselves with a solid historical performance. They are long term holders and builders of businesses. Cash flow is good and they have turned a profit every year for the last 20 years. Unlock Premium - Try 5i Free
TOP PICK
TOP PICK
September 22, 2020
Stockchase Research Editor: Michael O'Reilly eCommerce trade has benefitted during the pandemic and this is one of the major companies that delivers the goods. UPS just received an upgrade by analysts at Credit Suisse,. It is a defensive holding that continues to see revenues growing by double-digits. It pays a good dividend backed by a decent payout ratio. The technical chart is setting up for another push higher. We would trade this with a stop-loss at $145. Yield 2.51%
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly eCommerce trade has benefitted during the pandemic and this is one of the major companies that delivers the goods. UPS just received an upgrade by analysts at Credit Suisse,. It is a defensive holding that continues to see revenues growing by double-digits. It pays a good dividend backed by a decent payout ratio. The technical chart is setting up for another push higher. We would trade this with a stop-loss at $145. Yield 2.51%
TOP PICK
TOP PICK
September 22, 2020
Stockchase Research Editor: Michael O'Reilly NOC is a security company providing products like autonomous systems and cybersecurity and it operates in the US, Asia-Pacific and internationally. It has over $70 billion in backlog orders, which are principally with government agencies like the US Defense department. Recent earnings were up 19% with a 53% increase in free cash flow and the company increased its earnings guidance. We would trade this with a stop-loss at $295. Yield 1.78% (Analysts’ price target is $393.18)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly NOC is a security company providing products like autonomous systems and cybersecurity and it operates in the US, Asia-Pacific and internationally. It has over $70 billion in backlog orders, which are principally with government agencies like the US Defense department. Recent earnings were up 19% with a 53% increase in free cash flow and the company increased its earnings guidance. We would trade this with a stop-loss at $295. Yield 1.78% (Analysts’ price target is $393.18)
TOP PICK
TOP PICK
September 22, 2020
Stockchase Research Editor: Michael O'Reilly With the recent pullback from $150 highs, this is a good opportunity to enter. Rising revenues, profit margins and EPS are propelling this company, which has been an essential service provider during the pandemic. As retail bankruptcies rise in the US, there is a growing gap for WMT to fill. Dividends have grown for 47 consecutive years and are backed by a 34% payout ratio. We would buy this with a stop-loss at $120. Yield 1.58% (Analysts’ price target is $145.88)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly With the recent pullback from $150 highs, this is a good opportunity to enter. Rising revenues, profit margins and EPS are propelling this company, which has been an essential service provider during the pandemic. As retail bankruptcies rise in the US, there is a growing gap for WMT to fill. Dividends have grown for 47 consecutive years and are backed by a 34% payout ratio. We would buy this with a stop-loss at $120. Yield 1.58% (Analysts’ price target is $145.88)
TOP PICK
TOP PICK
September 22, 2020
The AGM is tomorrow. They provide e-commerce software to big companies like Sobey's, just like Shopify does for smaller ones. Also, they enable suppliers to bid on government contracts; MDF just won a big contract in this business in the UK. 80% of their sales are recurring, but it trades at only 1.5x recurring revenues vs. 30-40x among peers. A no-brainer. You will do extremely well with this. Investors associate MDF with its hodge-podge of accumulated internet platforms over years, but new managers are focusing on their winning core platforms. He expects new contract coming, helped by the online trend. (Analysts’ price target is $8.85)
The AGM is tomorrow. They provide e-commerce software to big companies like Sobey's, just like Shopify does for smaller ones. Also, they enable suppliers to bid on government contracts; MDF just won a big contract in this business in the UK. 80% of their sales are recurring, but it trades at only 1.5x recurring revenues vs. 30-40x among peers. A no-brainer. You will do extremely well with this. Investors associate MDF with its hodge-podge of accumulated internet platforms over years, but new managers are focusing on their winning core platforms. He expects new contract coming, helped by the online trend. (Analysts’ price target is $8.85)
TOP PICK
TOP PICK
September 22, 2020
They just struck a deal with the US Air Force. BB is highly undervalued and the most unloved Canadian tech company, purely specializing in security. They have several recurring revenue streams, including enterprise security, their core business, and car security that serves 175 million autos. They don't get investor love because they missed guidance a few times and a few shareholder have filed complaints about the board. He expects changes to the board. This explains the current stock hit. A great acquisition candidiate for a big tech company like MSFT. (Analysts’ price target is $5.49)
They just struck a deal with the US Air Force. BB is highly undervalued and the most unloved Canadian tech company, purely specializing in security. They have several recurring revenue streams, including enterprise security, their core business, and car security that serves 175 million autos. They don't get investor love because they missed guidance a few times and a few shareholder have filed complaints about the board. He expects changes to the board. This explains the current stock hit. A great acquisition candidiate for a big tech company like MSFT. (Analysts’ price target is $5.49)
TOP PICK
TOP PICK
September 22, 2020
They took a credibility hit after the Canadian army named them for several infractions at some retirement homes during the spring lockdown (some seniors died of Covid in Sienna home). They since made major management changes to beef up staff. The dividend is sustainable. The cost of operating these seniors' facililities has risen, though the government is covering a part of this cost and is thinking of helping to further fund home upgrades. (Analysts’ price target is $14.02)
Show full opinionHide full opinionThey took a credibility hit after the Canadian army named them for several infractions at some retirement homes during the spring lockdown (some seniors died of Covid in Sienna home). They since made major management changes to beef up staff. The dividend is sustainable. The cost of operating these seniors' facililities has risen, though the government is covering a part of this cost and is thinking of helping to further fund home upgrades. (Analysts’ price target is $14.02)
TOP PICK
TOP PICK
September 21, 2020
Warning about all his top picks: Markets are volatile and demand active management. This current pullback is a buying opportunity for ATVI. Buy a quarter and add at every $7 it falls down. He likes the videogame space, because people are staying at home during the pandemic and are driving subscriptions. New games like Call of Duty will increase earnings, even surprise. (Analysts’ price target is $95.16)
Show full opinionHide full opinionWarning about all his top picks: Markets are volatile and demand active management. This current pullback is a buying opportunity for ATVI. Buy a quarter and add at every $7 it falls down. He likes the videogame space, because people are staying at home during the pandemic and are driving subscriptions. New games like Call of Duty will increase earnings, even surprise. (Analysts’ price target is $95.16)
TOP PICK
TOP PICK
September 21, 2020
It's the darling of the semis, a super secular growth story. He targets $552.50. With the purchase of ARM, it puts Nvidia in a position of strength to lead the A.I. revolution in the coming years. There are regulatory hurdles and customer concerns, though. Buy a third now, then add another third at $490, then $425, and the final tranche at $350. (Analysts’ price target is $554.47)
Show full opinionHide full opinionIt's the darling of the semis, a super secular growth story. He targets $552.50. With the purchase of ARM, it puts Nvidia in a position of strength to lead the A.I. revolution in the coming years. There are regulatory hurdles and customer concerns, though. Buy a third now, then add another third at $490, then $425, and the final tranche at $350. (Analysts’ price target is $554.47)
TOP PICK
TOP PICK
September 21, 2020
A leader in data analytics, analyzing a company's data and actionable offering results to managers. They've shifted to a subscription model that investors love. They have competitors, but their focus on machine data is unique. They've shifted business to the cloud and a a result its rate prturn has soared. SPLK has been around for a long time. They target $1 billion in cash flows by 2023. He targets $230. Buy a third now, buy at $150, then at $125. (Analysts’ price target is $238.44)
Show full opinionHide full opinionA leader in data analytics, analyzing a company's data and actionable offering results to managers. They've shifted to a subscription model that investors love. They have competitors, but their focus on machine data is unique. They've shifted business to the cloud and a a result its rate prturn has soared. SPLK has been around for a long time. They target $1 billion in cash flows by 2023. He targets $230. Buy a third now, buy at $150, then at $125. (Analysts’ price target is $238.44)
TOP PICK
TOP PICK
September 21, 2020
Billy Kawasaki’s Insights - Picks from 5i Research. A renewable power producer. It has done well although it is expensive, trading around 71x earnings. They enjoy good earnings prospects and sales have doubled in past years. They have a lot of debt but cash flow is growing quickly. An aggressive choice in the sector. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Picks from 5i Research. A renewable power producer. It has done well although it is expensive, trading around 71x earnings. They enjoy good earnings prospects and sales have doubled in past years. They have a lot of debt but cash flow is growing quickly. An aggressive choice in the sector. Unlock Premium - Try 5i Free
TOP PICK
TOP PICK
September 18, 2020
It is well-positioned to benefit from the potential M&A wave. They are backed by CPP. It is a cashflow machine. A name that has meaningful upside once people want to own the sector. (Analysts’ price target is $2.58)
Show full opinionHide full opinionIt is well-positioned to benefit from the potential M&A wave. They are backed by CPP. It is a cashflow machine. A name that has meaningful upside once people want to own the sector. (Analysts’ price target is $2.58)
TOP PICK
TOP PICK
September 18, 2020
They recently made an acquisition. The ability to transact is important and the stock has done well. They will continue to be active in mergers and acquisitions. A 20-30% cashflow yield. (Analysts’ price target is $3.55)
Show full opinionHide full opinionThey recently made an acquisition. The ability to transact is important and the stock has done well. They will continue to be active in mergers and acquisitions. A 20-30% cashflow yield. (Analysts’ price target is $3.55)
TOP PICK
TOP PICK
September 18, 2020
They own land and people pay them to drill on it. The stock has fallen just as much as other names in the energy sector. There was a change in CEO who may be able to communicate better than the last one. Trading at a massive discount. (Analysts’ price target is $6.17)
Show full opinionHide full opinionThey own land and people pay them to drill on it. The stock has fallen just as much as other names in the energy sector. There was a change in CEO who may be able to communicate better than the last one. Trading at a massive discount. (Analysts’ price target is $6.17)
TOP PICK
TOP PICK
September 18, 2020
Billy Kawasaki’s Insights - Picks from 5i Research. It has high quality assets and a strong return history. Although the fund charges higher fees, it is justified considering the good performance record and healthy distribution history. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Picks from 5i Research. It has high quality assets and a strong return history. Although the fund charges higher fees, it is justified considering the good performance record and healthy distribution history. Unlock Premium - Try 5i Free
TOP PICK
TOP PICK
September 17, 2020
If we start to see slowing growth, plus inflation, and so stagflation, these are inflation-protected sovereign bonds. These are government of Canada bonds. You get the yield plus inflation. Nice complement to your bond portfolio. Yield is 2.14%.
Show full opinionHide full opinionIf we start to see slowing growth, plus inflation, and so stagflation, these are inflation-protected sovereign bonds. These are government of Canada bonds. You get the yield plus inflation. Nice complement to your bond portfolio. Yield is 2.14%.
TOP PICK
TOP PICK
September 17, 2020
New product. The largest market in the world is OTC rates. Helps hedge against relative interest rate movements. Allows your portfolio to profit from changes in the regimes of growth, volatility and inflation. Yield is 3.62%.
Show full opinionHide full opinionNew product. The largest market in the world is OTC rates. Helps hedge against relative interest rate movements. Allows your portfolio to profit from changes in the regimes of growth, volatility and inflation. Yield is 3.62%.
TOP PICK
TOP PICK
September 17, 2020
Canadians are in the unique position of having access to cryptocurrency. It's a closed-ended fund, so you have to be careful how you buy it. Management fee is a little higher. Access to an emerging access class in the "explore" portion of your portfolio.
Show full opinionHide full opinionCanadians are in the unique position of having access to cryptocurrency. It's a closed-ended fund, so you have to be careful how you buy it. Management fee is a little higher. Access to an emerging access class in the "explore" portion of your portfolio.
TOP PICK
TOP PICK
September 17, 2020
Stockchase Research Editor: Michael O'Reilly XRX has been a laggard during the pandemic as office workers have been remotely working. As employees begin a return to the office environment demand for the company's products will begin to return. Meanwhile the stock is quietly building a solid foundation. Carl Icahn has been accumulating shares steadily through August and purchased another $3 million worth of the stock so far in September. In its latest earnings the company produced $0.15 EPS, when analysts expected a breakeven, even in the face of a 35% drop in revenues. An area of future growth is in their liquid metal 3D printing solution -- allowing companies to manufacture much needed parts with off the shelf alloys. On a measured move basis, we see upside to $25 -- almost 30% upside. It is trading at 74% of book value, with a low historic PE, and offers an attractive yield that is backed by a 28% payout ratio. We would trade this with a $15 stop loss. Yield 5.20% (Analysts’ price target is $18.25)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly XRX has been a laggard during the pandemic as office workers have been remotely working. As employees begin a return to the office environment demand for the company's products will begin to return. Meanwhile the stock is quietly building a solid foundation. Carl Icahn has been accumulating shares steadily through August and purchased another $3 million worth of the stock so far in September. In its latest earnings the company produced $0.15 EPS, when analysts expected a breakeven, even in the face of a 35% drop in revenues. An area of future growth is in their liquid metal 3D printing solution -- allowing companies to manufacture much needed parts with off the shelf alloys. On a measured move basis, we see upside to $25 -- almost 30% upside. It is trading at 74% of book value, with a low historic PE, and offers an attractive yield that is backed by a 28% payout ratio. We would trade this with a $15 stop loss. Yield 5.20% (Analysts’ price target is $18.25)
TOP PICK
TOP PICK
September 17, 2020
Stockchase Research Editor: Michael O'Reilly We are once again cautioning against a possible market retracement and are recommending this inverse S&P500 ETF as a Top Pick. As it is priced in Canadian dollars it will receive added benefit from a weakening in the Canadian dollar if the market retraces. We recommend this as a hedge against dividend paying stocks. It has a very low MER as well.
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly We are once again cautioning against a possible market retracement and are recommending this inverse S&P500 ETF as a Top Pick. As it is priced in Canadian dollars it will receive added benefit from a weakening in the Canadian dollar if the market retraces. We recommend this as a hedge against dividend paying stocks. It has a very low MER as well.
TOP PICK
TOP PICK
September 17, 2020
Stockchase Research Editor: Michael O'Reilly Thus utilities based ETF is a defensive holding that provides a solid yield. This can act as a hedge against investor equity holding in case of a broad market retracement. Utility holdings also benefit during a prolonged low interest rate environment. We would trade this with a $54 stop-loss.
Yield 3.38%
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly Thus utilities based ETF is a defensive holding that provides a solid yield. This can act as a hedge against investor equity holding in case of a broad market retracement. Utility holdings also benefit during a prolonged low interest rate environment. We would trade this with a $54 stop-loss.
Yield 3.38%
TOP PICK
TOP PICK
September 16, 2020
Second largest operator behind 7-11. As Covid restrictions loosen, we'll have more people on the road but also driving rather than using public transportation. Good job of thinking about the future. Launching own brand of food, exploring initiatives in e-charging stations and selling marijuana. Free cash flow has grown 16% over the last 5 years, dividend grows at 22%. Yield is 0.63%. (Analysts’ price target is $51.54)
Show full opinionHide full opinionSecond largest operator behind 7-11. As Covid restrictions loosen, we'll have more people on the road but also driving rather than using public transportation. Good job of thinking about the future. Launching own brand of food, exploring initiatives in e-charging stations and selling marijuana. Free cash flow has grown 16% over the last 5 years, dividend grows at 22%. Yield is 0.63%. (Analysts’ price target is $51.54)
TOP PICK
TOP PICK
September 16, 2020
Choline product necessary to humans and animals. Also make a purifier for when you don't have water. Through Covid, EBITDA, revenue, and EPS all increased. Grow through acquisition and organically. Prudent with the debt they take on. About 12% free cash flow growth per year. Smart management team. Yield is 0.54%. (Analysts’ price target is $109.25)
Show full opinionHide full opinionCholine product necessary to humans and animals. Also make a purifier for when you don't have water. Through Covid, EBITDA, revenue, and EPS all increased. Grow through acquisition and organically. Prudent with the debt they take on. About 12% free cash flow growth per year. Smart management team. Yield is 0.54%. (Analysts’ price target is $109.25)
TOP PICK
TOP PICK
September 16, 2020
Global leader in enzymes, 48% market share. Dividend has grown by 16% since 2000. Stock's been trading sideways, so with share buybacks investors get a bigger piece of the pie. 34% of sales come from EM. Enzymes are low in cost, but have a big impact on the outcome. Yield is 1.27%.
Show full opinionHide full opinionGlobal leader in enzymes, 48% market share. Dividend has grown by 16% since 2000. Stock's been trading sideways, so with share buybacks investors get a bigger piece of the pie. 34% of sales come from EM. Enzymes are low in cost, but have a big impact on the outcome. Yield is 1.27%.
TOP PICK
TOP PICK
September 15, 2020
A regulated utility and they make green energy. 90% of revenues come from the U.S. It's defensive with a visible cash flow. Their renewable business is supported by long-term contracts. The 4.5% dividend is safe and will continue to rise. AQN recently raised $1 billion to fund their capital program this year into next. They've partnered with Chevron to develop their renewable energy. Last week, they bought a Chilean water utility and may buy the rest of it later. Overall, they're expanding their renewable power space. They have room to grow geographically here and abroad. Strong growth prospects here and an income stock. We're already seeing capital pour into renewable power globally and here in Canada. (Analysts’ price target is $20.59)
A regulated utility and they make green energy. 90% of revenues come from the U.S. It's defensive with a visible cash flow. Their renewable business is supported by long-term contracts. The 4.5% dividend is safe and will continue to rise. AQN recently raised $1 billion to fund their capital program this year into next. They've partnered with Chevron to develop their renewable energy. Last week, they bought a Chilean water utility and may buy the rest of it later. Overall, they're expanding their renewable power space. They have room to grow geographically here and abroad. Strong growth prospects here and an income stock. We're already seeing capital pour into renewable power globally and here in Canada. (Analysts’ price target is $20.59)
TOP PICK
TOP PICK
September 15, 2020
A diversified healthcare name. The pharma drug pipeline is robust with success launching products that should continue. Strong balance sheet and pays under a 3% yield that they've increased in 50 straight years. The medical devices unit got hit by the lockdown, but surgeries are coming back (they reportedly snapped back to 85% pre-Covid). They are developing a vaccine, but won't make a profit, they say, in the first stage. (Analysts’ price target is $163.63)
Show full opinionHide full opinionA diversified healthcare name. The pharma drug pipeline is robust with success launching products that should continue. Strong balance sheet and pays under a 3% yield that they've increased in 50 straight years. The medical devices unit got hit by the lockdown, but surgeries are coming back (they reportedly snapped back to 85% pre-Covid). They are developing a vaccine, but won't make a profit, they say, in the first stage. (Analysts’ price target is $163.63)